Tackling the remaining challenges of multiple sclerosis

With Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond and MS expert Dr Xavier Montalban to get their views on the biggest hurdles to overcome in this difficult-to-treat disease.